Structural requirements for potent anti-human immunodeficiency virus (HIV) and sperm-immobilizing activities of cyclohexenyl thiourea and urea non-nucleoside inhibitors of HIV-1 reverse transcriptase

Biology of Reproduction

Volumn 67, Issue 6, 2002, Pages 1959-1974

  D'Cruz, Osmond J ^a,b   Venkatachalam, Taracad K ^a   Mao, Chen ^a   Qazi, Sanjive ^a   Uckun, Fatih M ^a  

^a PARKER HUGHES INSTITUTE   (United States)

^b Paradigm Pharmaceuticals   (United States)

Author keywords

Sperm; Sperm motility and transport; Vagina

Indexed keywords

CYCLOHEXENYLTHIOUREA DERIVATIVE; N [2 (1 CYCLOHEXENYL)ETHYL] N' [2 (5 BROMOPYRIDYL)]THIOUREA; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; SPERMICIDAL AGENT; THIOUREA DERIVATIVE; UNCLASSIFIED DRUG; UREA DERIVATIVE; AMINOPYRIDINE DERIVATIVE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; DRUG DERIVATIVE; N (2 (1 CYCLOHEXENYL)ETHYL) N' (2 (5 BROMOPYRIDYL)) UREA; N (2 (1 CYCLOHEXENYL)ETHYL) N' (2 (5 BROMOPYRIDYL))THIOUREA; N-(2-(1-CYCLOHEXENYL)ETHYL)-N'-(2-(5-BROMOPYRIDYL))-UREA; N-(2-(1-CYCLOHEXENYL)ETHYL)-N'-(2-(5-BROMOPYRIDYL))THIOUREA; THIOUREA; UREA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ARTIFICIAL INSEMINATION; COMPUTER ANALYSIS; CONTROLLED STUDY; DRUG SYNTHESIS; GENOTYPE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HYDROPHOBICITY; MICROEMULSION; NONHUMAN; PHENOTYPE; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION; RABBIT; SEMEN ANALYSIS; SPERMATOZOON MOTILITY; VIRUS REPLICATION; ANIMAL; ANTIBIOTIC RESISTANCE; CHEMISTRY; DRUG ANTAGONISM; DRUG EFFECT; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS 1; KINETICS; PREGNANCY; STRUCTURE ACTIVITY RELATION;

ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; ORYCTOLAGUS CUNICULUS; SIA;

AMINOPYRIDINES; ANIMALS; ANTI-HIV AGENTS; CHEMISTRY, PHYSICAL; DRUG RESISTANCE, MICROBIAL; FEMALE; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; INSEMINATION, ARTIFICIAL; KINETICS; PREGNANCY; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; RABBITS; REVERSE TRANSCRIPTASE INHIBITORS; SPERM MOTILITY; SPERMATOCIDAL AGENTS; STRUCTURE-ACTIVITY RELATIONSHIP; THIOUREA; UREA;

EID: 0036892224     PISSN: 00063363     EISSN: None     Source Type: Journal    
DOI: 10.1095/biolreprod.102.006478     Document Type: Article

References (66)

1. Quinn TC. Global burden of the HIV pandemic. Lancet 1996; 348: 99-106.
2. Centers for Disease Control and Prevention (CDC). HIV/AIDS Surveillance Report 2000; 12:1-44.
3. UNAIDS. Report on the Global HIV/ADS Epidemic; December 2001.
4. HIV Infection in Women. National Institute of Allergy and Infectious Diseases Fact Sheet; May 2001.
5. Rivers K, Aggleton P. Women & HIV, Adolescent sexuality, gender, and the HIV epidemic. BETA 2001; 14:35-40.
6. Gayle H. An overview of the global HIV/AIDS epidemic, with a focus on the United States. AIDS 2000; 14(suppl 2):S8-17.
7. Hodge CE. HIV/AIDS: Impact on the African American community. Compend Contin Educ Dent 2001; 22:52-56.
8. Potts M. The urgent need for a vaginal microbicide in the prevention of HIV transmission [editorial]. Am J Public Health 1994; 84:890-891.
9. Uckun FM, D'Cruz OJ. Prophylactic contraceptives for HIV/AIDS. Hum Reprod Update 1999; 5:506-514.
10. Lange JMA, Karam M, Plot P. Boost for vaginal microbicides against HIV. Lancet 1993; 341:1356-1359.
11. Cookson C. WHO to concentrate HIV strategy on vaginal microbicide. Br Med J 1993; 307:1375-1376.
12. Mitsuya H, Yarchoan R, Broder S. Molecular targets for AIDS therapy. Science 1990; 249:1533-1544.
13. Mao C, Sudbeck EA, Venkatachalam TK, Uckun FM. Structure-based drug design of non-nucleoside inhibitors for wild-type and drug-resistant HIV reverse transcriptase. Biochem Pharmacol 2000; 60:1251-1265.
14. De Clercq E. Inhibitors targeted at the reverse transcriptase. J Acquir Immune Defic Syndr Res Human Retrovirol 1992; 8:119-134.
15. Smerdon SJ, Jager J, Wang J, Kohlstaedt LA, Chirino AJ, Friedman JM, Rice PA, Steitz TA. Structure of the binding site for nonnucleoside inhibitors of the reverse transcriptase of human immunodeficiency virus type 1. Proc Natl Acad Sci U S A 1994; 91:3911-3915.
16. Ren J, Esnouf R, Garman E, Somers D, Ross C, Kirby I, Keeling J, Darby G, Jones Y, Stuart D, Stammers D. High resolution structures of HIV-1 RT from four RT-inhibitor complexes. Nat Struct Biol 1995; 2:293-302.
17. Ding J, Das K, Tantillo C, Zhang W, Clark AD Jr, Jessen S, Lu X, Hsiou Y, Jacobo-Molina A, Andries K, Pauwels R, Moereels H, Koymans L, Janssen PAJ, Smith RHJ, Kroeger-Koepke R, Michejda CJ, Hughes SH, Arnold E. Structure of HIV-1 reverse transcriptase in a complex with the non-nucleoside inhibitor alpha-APA R 95845 at 2.8 A resolution. Structure 1995; 3:365-379.
18. Klunder JM, Hoermann M, Cywin CL, David E, Brickwood JR, Schwartz R, Barringer KJ, Pauletti D, Shih CK, Erickson DA, Sorge CL, Joseph DP, Hattox SE, Adams J, Grob PM. Novel nonnucleoside inhibitors of HIV-1 reverse transcriptase. 7.8-Arylethyldipyridodiazepinones as potent broad-spectrum inhibitors of wild-type and mutant enzymes. J Med Chem 1998; 41:2960-2971.
19. Romero DL, Olmsted RA, Poel TJ, Morge RA, Biles C, Keiser BJ, Kopta LA, Friis JM, Hosley JD, Stefanski KJ, Wishka DG, Evans DB, Morris J, Stehle RG, Sharma SK, Yagi Y, Voorman RL, Adams WJ, Tarpley WG, Thomas RC. Targeting delavirdine/atevirdine resistant HIV-1: Identification of (alkylamino)piperidine-containing bis(heteroaryl)piperazines as broad spectrum HIV-1 reverse transcriptase inhibitors. J Med Chem 1996; 39:3769-3789.
20. Young SD, Britcher SF, Tran LO, Payne LS, Lumma WC, Lyle TA, Huff JR, Anderson PS, Olsen DB, Carroll SS, Pettibone DJ, O'Brien JA, Ball RG, Balani SK, Lin JH, Chen I-W, Schleif WA, Sardana VV, Long WJ, Byrnes VW, Emini EA. L-743, 726 (DMP-266): A novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother 1995; 39:2602-2605.
21. Albrecht MA, Bosch RJ, Hammer SM, Liou SH, Kessler H, Para MF, Eron J, Valdez H, Dehlinger M, Katzenstein DA. Nelfinavir, efavirenz, or both after the failure of nucleoside treatment of HIV infection. N Engl J Med 2001; 345:398-407.
22. Miles SA. HIV infection and AIDS: New biology, therapeutic advances, and clinical implications. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 16:S1-S2.
23. Havlir DV, Richman DD. Viral dynamics of HIV: Implications for drug development and therapeutic strategies. Ann Intern Med 1996; 124:984-994.
24. Miles SA. Long-term therapeutic strategies in HIV. Immune Defic Syndr Hum Retrovirol 1997; 16:S36-S41.
25. Kohlstaedt LA, Wang J, Friedman JM, Rice PA, Steitz TA, Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science 1992; 256:1783-1790.
26. Ren J, Esnouf R, Hopkins A, Ross C, Jones Y, Stammers D, Stuart D. The structure of HIV-1 reverse transcriptase complexed with 9-chloro-TIBO: Lessons for inhibitor design. Structure 1995; 3:915-926.
27. Sudbeck EA, Mao C, Vig R, Venkatachalam TK, Tuel-Ahlgren L, Uckun FM. Structure-based design of novel dihydroalkoxybenzyloxopyrimidine derivatives as potent nonnucleoside inhibitors of the human immunodeficiency virus reverse transcriptase. Antimicrob Agents Chemother 1998; 42:3225-3233.
28. De Clercq E. Antiviral drugs: Current state of the art. J Clin Virol 2001; 22:73-89.
29. Vig R, Mao C, Venkatachalam TK, Tuel-Ahlgren L, Sudbeck E, Uckun FM. Rational design and synthesis of phenethyl-5-bromopyridyl thiourea derivatives as potent non-nucleoside inhibitors of HIV reverse transcriptase. Bioorg Med Chem 1998; 6:1789-1797.
30. Mao C, Vig R, Venkatachalam TK, Sudbeck EA, Uckun FM. Structure-based design of N-[2-(1-piperidinylethyl)-N′-[2-(5-bromopyridyl)]-thiourea and N-[2-(1-piperazinylethyl)-N′-[2-(5-bromopyridyl)]-thiourea as potent non-nucleoside inhibitors of HIV-1 reverse transcriptase. Bioorg Med Chem Lett 1998; 8:2213-2218.
31. Uckun FM, Mao C, Pendergrass S, Maher D, Zhu D, Tuel-Ahlgren L, Venkatachalam TK. N-[2-(1-cyclohexenyl)ethyl]-N′-[2-(5-bromopyridyl)]-thiourea and N′-[2-(1-cyclohexenyl)ethyl]-N′-[2-(5-chloropyridyl)]-thiourea as potent inhibitors of multidrug-resistant human immunodeficiency virus-1. Bioorg Med Chem Lett 1999; 9:2721-2726.
32. Mao C, Sudbeck EA, Venkatachalam TK, Uckun FM. Structure-based design of non-nucleoside reverse transcriptase inhibitors of drug-resistant human immunodeficiency virus. Antiviral Chem Chemother 1999; 10:233-240.
33. Uckun FM, Pendergrass S, Maher D, Zhu D, Tuel-Ahlgren L, Mao C, Venkatachalam TK. N′-[2-(2-thiophene)ethyl]-N′-[2-(5-bromopyridyl)] thiourea as a potent inhibitor of NNI-resistant and multidrug-resistant human immunodeficiency virus-1. Bioorg Med Chem Lett 1999; 9:3411-3416.
34. Uckun FM, Mao C, Pendergrass S, Maher D, Zhu D, Tuel-Ahlgren L, Venkatachalam TK. N-[2-(4-methylphenyl)ethyl]-N′-[2-(5-bromopyridyl)]-thiourea as a potent inhibitor of NNRTI-resistant and multidrug-resistant human immunodeficiency virus type 1. Antiviral Chem Chemother 2000; 11:135-140.
35. Venkatachalam TK, Sudbec EA, Mao C, Uckun FM. Piperidinylethyl, phenoxyethyl and fluoroethyl bromopyridyl thiourea compounds with potent anti-HIV activity. Antiviral Chem Chemother 2000; 11:329-336.
36. Venkatachalam TK, Sudbeck EA, Mao C, Uckun FM. Anti-HIV activity of aromatic and heterocyclic thiazolyl thiourea compounds. Bioorg Med Chem Lett 2001; 11:523-528.
37. Mao C, Sudbeck EA, Venkatachalam TK, Uckun FM. Rational design of N-[2-(2,5-dimethoxyphenylethyl)]-N′-[2-(5-bromopyridyl)]-thiourea (HI-236) as a potent non-nucleoside inhibitor of drug-resistant human immunodeficiency virus. Bioorg Med Chem Lett 1999; 9:1593-1598.
38. Venkatachalam TK, Mao C, Uckun FM. Stereochemistry as a major determinant of the anti-HIV activity of chiral naphthyl thiourea compounds. Antiviral Chem Chemother 2001; 12:213-221.
39. Venkatachalam TK, Sudbeck EA, Mao C, Uckun FM. Stereochemistry of halopyridyl and thiazolyl thiourea compounds is a major determinant of their potency as nonnucleoside inhibitors of HIV-1 reverse transcriptase. Bioorg Med Chem Lett 2000; 10:2071-2074.
40. D'Cruz OJ, Venkatachalam TK, Uckun FM. Novel thiourea compounds as dual-function microbicides. Biol Reprod 2000; 63:196-205.
41. Bosworth N, Towers P. Scintillation proximity assay. Nature 1989; 341:167-168.
42. Zarling JM, Moran PA, Haffar O, Diegel M, Myers DE, Kuelbeck V, Ledbetter JA, Uckun FM. Inhibition of HIV-1 replication in seropositive patients' CD4+ T-cells by pokeweed antiviral protein-monoclonal antibody conjugates. Int J Immunopharmacol 1991; 13(suppl 1): 63-68.
43. Zarling JM, Moran PA, Haffar O, Sias J, Richman DD, Spina CA, Myers DE, Kuebelbeck V, Ledbetter JA, Uckun FM. Inhibition of HIV replication by pokeweed antiviral protein targeted to CD4+ cells by monoclonal antibodies. Nature 1990; 347:92-95.
44. Uckun FM, Chelstrom LM, Ahlgren-Tuel L, Dibirdik L, Irvin JD, Langlie M-C, Myers DE. TXU (anti-CD7)-pokeweed antiviral protein as a potent inhibitor of human immunodeficiency virus. Antimicrob Agents Chemother 1998; 42:383-388.
45. D'Cruz OJ, Venkatachalam TK, Zhu Z, Shih M-J, Uckun FM. Bromomethoxy and aryl phosphate derivatives of azidothymidine are dualfunction spermicides with potent anti-HIV activity. Biol Reprod 1998; 59:503-515.
46. D'Cruz OJ, Ghosh P, Uckun FM. Spermicidal activity of metallocene complexes containing vanadium(IV) in humans. Biol Reprod 1998; 58:1515-1526.
47. D'Cruz OJ, Venkatachalam TK, Uckun FM. Structural requirements for potent human spermicidal activity of dual-function aryl phosphate derivative of bromo-methoxy zidovudine (compound WHI-07). Biol Reprod 2000; 62:37-44.
48. D'Cruz OJ, Uckun FM. Pokeweed antiviral protein: A potential non-spermicidal prophylactic antiviral agent. Fertil Steril 2001; 75:106-114.
49. D'Cruz OJ, Uckun FM, Novel derivatives of phenethyl-5-bromopyridylthiourea (PBT) and dihydroalkoxybenzyloxopyrimidine dine (DABO) are dual-function spermicides with potent anti-HIV activity. Biol Reprod 1999; 60:1419-1428.
50. D'Cruz OJ, Venkatachalam TK, Uckun FM, Thymidine kinase-independent intracellular delivery of bioactive nucleotides by aryl phosphate derivatives of bromo-methoxy zidovudine (compounds WHI-05 and WHI-07) in normal human female genital tract epithelial cells and sperm. Biol Reprod 2001; 64:51-59.
51. D'Cruz OJ, Dong Y, Uckun FM. Apoptosis-inducing oxovanadium(IV) complexes of 1,10-phenanthroline against human ovarian cancer. Anticancer Drugs 2000; 11:849-858.
52. De Geyter C, Bals-Pratsch M, Doeren M, Yeung CH, Grunert JH, Bordt J, Schneider HP, Nieschlag E. Human and bovine cervical mucus penetration as a test of sperm function for in-vitro fertilization. Hum Reprod 1988; 3:948-954.
53. Rogers D, Hopfinger AJ, Application of genetic function approximation to quantitative structure activity relationships and quantitative structure property relationships. J Chem Inf Comp Sci 1994; 34:854-866.
54. D'Cruz OJ, Yiv SH, Waurzyniak B, Uckun FM. Contraceptive efficacy and safety studies of a novel microemulsion-based lipophilic vaginal spermicide. Fertil Steril 2001; 75:115-124.
55. D'Cruz OJ, Uckun FM. Gel-microemulsions as vaginal spermicides and intravaginal drug delivery vehicles. Contraception 2001; 64:113-123.
56. International Working Group on Vaginal Microbicides. Recommendations for the development of vaginal microbicides. AIDS 1996; 10: UNAIDS1-UNAIDS6.
57. Ecstein P, Jackson MC, Millman N, Sobrero AJ. Comparison of vaginal tolerance tests of spermicidal preparations in rabbits and monkeys. J Reprod Fertil 1969; 20:85-93.
58. Kukla MJ, Breslin HJ, Diamond CJ, Grous PP, Ho CY, Miranda M, Rodgers JD, Sherrill RG, De Clercq E, Pauwels R, Andries K. Synthesis and anti-HIV-1 activity of 4,5,6,7-tetrahydro-5-methylimidazo[4,5,1-jk][1,4]benzodiazepin-2(1H)-one (TIBO) derivatives. 2. J Med Chem 1991; 34:3187-3197.
59. Sahlberg C, Noreen R, Engelhardt P, Hogberg M, Kangasmetsa J, Vrang L, Zhang H. Synthesis and anti-HIV activities of urea-PETT analogs belonging to a new class of potent non-nucleoside HIV-1 reverse transcriptase inhibitors. Bioorg Med Chem Lett 1998; 8:1511-1516.
60. Crank G, Mursyidi A. Oxidation of thiourea with photochemically generated singlet oxygen. J Photochem Photobiol A 1992; 64:263-271.
61. Dong Y, Venkatachalam TK, Narla RK, Trieu VN, Sudbeck EA, Uckun FM. Antioxidant function of phenethyl-5-bromo-pyridyl thiourea compounds with potent anti-HIV activity. Bioorg Med Chem Lett 2000; 10:87-90.
62. D'Cruz OJ, Waurzyniak B, Uckun FM. A 13-week subchronic intravaginal toxicity study of the novel broad-spectrum anti-HIV and spermicidal agent, (N-[2-(1-cyclohexenyl)ethyl]N′-[2-(5-bromopyridinyl)]-thiourea), in mice. Toxicol Pathol 2002; 30:1-9.
63. Chen CL, Uckun FM. Evaluation of the pharmacokinetic features and tissue distribution of the potent nonnucleoside inhibitor of HIV-1 reverse transcriptase, N-[2-(2-fluorophenethyl)]-N′-[2-(5-bromopyridyl)]-thiourea (HI-240) with an analytical HPLC method. Pharmacol Res 1999; 16:1226-1232.
64. Chen CL, Venkatachalam TK, Waurzyniak B, Chelstrom L, Uckun FM. In vivo toxicity, pharmacokinetic features and tissue distribution of N-[2-(2,5-dimethoxyphenylethyl)]-N′-[2-(5-bromopyridyl)]-thiourea (H1-236), a potent non-nucleoside inhibitor of HIV-1 reverse transcriptase. Drug Res 2001; 51:574-581.
65. Brown D. Study finds drug-resistant HIV in half of infected patients. Washington Post News Report; December 19, 2001, p. A02.
66. Susman E. Many HIV patients carry mutated drug-resistant strains. Lancet 2002; 359:49.